Peyona

Caffeine

Method of action: Cardiotonic, Cns Stimulant, Enhancing The Body'S Resistance, Psychoanaleptics, Replenishing Deficiency Of Vitamins Of Group B, Tonic

Treatment option: Vascular Spasm

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Peyona

Peyona is a highly specialized, prescription-only medicine administered exclusively in neonatal intensive care settings for the treatment of respiratory challenges in infants. Its fundamental purpose is to act as a Central Nervous System Stimulant, helping to stabilize the breathing patterns of the most vulnerable patients. The product's focused utility for this specific population is clinically recognized within the field of neonatology.

Property	Description
Active ingredient	Caffeine citrate (Coffeini citras)
Form	Solution for infusion and oral solution
Pharmacological class	Central Nervous System Stimulant, Methylxanthine
General purpose	Management of primary apnoea of premature newborns
Origin	Synthetic

Definition, Composition, and Pharmacological Class

The active ingredient in this medicinal preparation is Caffeine citrate (Coffeini citras), which is chemically classified within the methylxanthine class, a group of xanthine derivatives. This compound is manufactured as a synthetic, single-ingredient substance to ensure the precise control and consistency necessary for use in neonates. Its unique positioning as a respiratory stimulant distinguishes it from other treatments used in pediatric care. The product is presented as a clear, colorless aqueous solution, confirming its standardized preparation.

Forms and General Therapeutic Purpose

The formulation of Peyona is a versatile solution for infusion and oral solution supplied in sealed ampoules. This dual-route capacity, allowing for both rapid Intravenous (IV) infusion and subsequent oral administration via a nasogastric tube, facilitates continuous care as the patient progresses. The general therapeutic purpose of the medicine is the management of primary apnoea of premature newborns, a common challenge characterized by extended pauses or interrupted breathing in premature babies who have not yet developed mature respiratory control. This application represents a typical, neutral use scenario for the drug.

The Essence of the Stimulant Mechanism

The mechanism of action for Caffeine citrate is rooted in its role as a non-specific adenosine receptor antagonist. In simple terms, this means it works by inhibiting the effect of adenosine, a natural chemical messenger that acts to slow down activity in the brain, including the vital respiratory center. By blocking this natural inhibitory signal, Peyona effectively stimulates the central respiratory drive, ensuring the frequency of breaths and tidal volume are maintained to reduce life-threatening apneic episodes in the preterm neonate.

What side effects are possible with Peyona?

Official Adverse Reactions

Regulatory documents detail the possible adverse reactions associated with Caffeine citrate, grouping them by frequency and the body system affected. These classifications reflect the officially documented risk profile.

Frequency-Classified Effects

Frequency Category	Adverse Reactions	System-Organ Class
Common (up to 1 in 10)	Tachycardia (Rapid heart rate), Hyperglycaemia (High blood sugar)	Cardiac disorders, Metabolism and nutrition disorders
Uncommon (up to 1 in 100)	Arrhythmia (Irregular heartbeat), Convulsion/Seizures	Cardiac disorders, Nervous system disorders
Frequency Not Known	Necrotising enterocolitis, Hypoglycaemia	Gastrointestinal disorders, Metabolism and nutrition disorders

Serious Documented Risks and Cautions

Official labeling identifies specific risks and mandatory monitoring requirements:

Serious Intestinal Risk: Necrotising enterocolitis (NEC) is a serious adverse reaction cited in regulatory documents. Patients require careful monitoring for any signs of this condition.
Toxicity: The risk of serious toxicity, including seizures, increases when serum caffeine concentrations exceed a specific level, prompting the need for therapeutic drug monitoring.
Contraindications: Peyona is contraindicated in individuals with known hypersensitivity to caffeine citrate or any component of the formulation.

Population-Specific Safety Notes

The safety profile includes special considerations for vulnerable patients:

Impaired Organ Function: Caution is required in infants with impaired renal or hepatic function due to the potential for the drug to accumulate and clear slowly from the body.
Very Premature Infants: Infants born before 28 weeks of gestation may be at an increased risk of elevated plasma levels, potentially requiring adjusted monitoring.
Time-Related Patterns: There is a potential for drug accumulation when treatment is extended, which must be considered due to the prolonged drug half-life in premature newborns.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Peyona overdose is defined by specific, documented signs of Central Nervous System (CNS) and cardiovascular hyperstimulation in premature newborns.

Overdose Manifestations and Actions

Element	Regulatory Statement
Documented Manifestations	Clinical signs include seizures, fine tremor, hypertonia, irritability, vomiting, and tachycardia (rapid heartbeat). Metabolic findings such as hyperglycaemia and hypokalaemia are also documented [Source 1.6, 1.2].
Serious Outcomes	Serious toxicity has been reported when plasma caffeine levels exceed 50 mg/L. Severe outcomes may include Intraventricular haemorrhage and long-term neurological sequelae [Source 1.5, 1.6].
Emergency Action	Regulatory guidance mandates to Seek immediate medical attention or Get emergency help immediately if signs of overdose are suspected [Source 1.2].

Supportive Management

Treatment for overdose is specified as symptomatic and supportive. This involves hospital monitoring of plasma caffeine, potassium, and glucose concentrations, with subsequent correction of any documented metabolic findings. Procedures like exchange transfusion have been shown to decrease high plasma caffeine concentrations [Source 1.6].

Note: Caution is advised in preterm neonates with impaired renal or hepatic function due to the potential for drug accumulation, which increases the risk of toxicity [Source 1.1, 1.3].

Therapeutic Uses of Peyona

What Peyona Treats: Main Uses and Benefits

Peyona is generally applied across domains where additional symptomatic support is needed, and is considered relevant within clinical settings that involve acute or unstable symptom patterns. It is commonly used in areas where short-term symptom management is appropriate, contributing to easing the overall burden of symptoms. This medication is relevant for easing symptoms that interfere with daily functioning.

The primary therapeutic use for Peyona is applied in addressing symptoms related to systemic imbalance and symptoms that create noticeable physiological strain, making it commonly used to help with conditions presenting with acute episodes. The medication’s role is supportive and may assist with maintaining functional stability.

Therapeutic Benefit

“Peyona provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms.” It assists with maintaining functional stability and supports general well-being during symptomatic phases.

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning Peyona is commonly used when supportive symptom management is appropriate in specialized clinical settings.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Peyona — Official Regulatory Information

The eligibility profile for Peyona (caffeine citrate) is strictly defined by government regulatory documents, limiting its use to a specialized, monitored population.

Category	Official Regulatory Statement
Populations for whom use is allowed	Premature newborns for the treatment of primary apnoea of prematurity.
Populations for whom use is contraindicated	Patients with known hypersensitivity to caffeine citrate or any component of the formulation.
Age-related eligibility rules	Indicated exclusively for premature newborns. Use in any other age group is not applicable.
Condition-specific eligibility rules	Use requires caution in infants with impaired renal function or impaired hepatic function due to the potential for drug accumulation.

Populations Requiring Conditional Use

Treatment must be administered with explicit caution for infants presenting with cardiovascular disease or a history of seizure disorders. Caution is also advised for those suffering from gastro-oesophageal reflux. The safety and efficacy for the prophylactic treatment of SIDS or use prior to extubation have not been established by regulatory authorities. Additionally, breast-feeding mothers of treated infants must avoid all caffeine-containing products.

What should I know about interactions with other medicines?

The official interaction profile for Peyona is structured around the unique metabolic limitations of premature neonates, where drug clearance is slower. Regulatory documents strictly prohibit the co-administration of the related methylxanthine, Theophylline, due to the documented inter-conversion of the substances in preterm infants, which can lead to accumulation.

Interactions affecting clearance are often mediated by the CYP450 1A2 (CYP1A2) enzyme pathway. Substances that decrease clearance, such as Cimetidine and Ketoconazole, may increase drug exposure. Conversely, agents that increase clearance, including Phenobarbital and Phenytoin, may reduce exposure. These pharmacokinetic interactions necessitate therapeutic plasma monitoring.

A risk-based interaction is noted for Antihistamine H2 receptor blockers and Proton-pump inhibitors, where concurrent use is theoretically associated with an increased risk of necrotising enterocolitis. Furthermore, a timing-based constraint requires baseline plasma caffeine concentrations to be measured in newborns previously treated with Theophylline.

Interaction-related restrictions prohibit the maternal consumption of coffee or high caffeine products during breastfeeding. Population-specific interaction cautions also exist, as infants with impaired renal or hepatic function face an increased potential for drug accumulation, requiring specialized monitoring as noted in regulatory labeling.

Mechanism of Action

How Peyona Works

Adenosine Receptor Antagonism

Peyona (caffeine citrate) exerts its primary action as a non-selective antagonist at central adenosine receptors (A1 and A2A). By occupying these binding sites, the drug prevents the inhibitory effects of endogenous adenosine, a neuromodulator that typically decreases neuronal activity. This suppression of adenosine-mediated signaling leads to a net increase in neuronal excitability within the central nervous system.

Influence on Respiratory Output

The drug modulates signaling pathways within the brainstem involved in respiratory rhythm generation. By counteracting the inhibitory influence of adenosine on respiratory neurons and increasing chemoreceptor sensitivity to carbon dioxide, Peyona enhances central respiratory drive. This mechanistic cascade results in changes to central respiratory output, influencing the frequency and depth of respiration.

Modulation of Neurotransmitter Release

The antagonism of adenosine receptors indirectly modifies molecular steps that influence the dopaminergic, noradrenergic, and serotonergic systems. This effect promotes increased neurotransmitter release and sustained neuronal excitability.

Dosage and Administration Information

Peyona is a medicine administered to premature newborns and must only be initiated within a Neonatal Intensive Care Unit (NICU) setting. The official regimen is based on the infant’s body weight and involves a two-phase administration pattern.

The treatment begins with a single loading dose of 20 mg caffeine citrate per kg body weight. This dose is administered by slow intravenous infusion over a period of 30 minutes. Following a 24-hour interval after the initial dose, the daily maintenance phase commences.

The maintenance dose is 5 mg/kg and is given once daily. It can be delivered either by slow IV infusion over 10 minutes or by oral administration. The medicine is typically continued until the infant has been stable for a period of five to seven days. The administration protocol does not require a gradual dose tapering upon cessation. For infants with impaired renal or hepatic function, official instructions require the monitoring of plasma drug concentrations to ensure the appropriate dose is maintained.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Peyona

Peyona (caffeine citrate) is a highly specialized medicine, and the medical community has conducted considerable research to characterize its use in neonatal intensive care settings. This section provides an overview of the types of studies that have been conducted and the patterns observed in the data, without offering medical advice or making claims about what the drug will do for any individual baby.

Evidence for the Management of Primary Apnoea of Premature Newborns

This section summarizes the structure of the clinical research for the drug’s primary use, detailing the types of studies that have been conducted and the specific short-term outcomes that were measured.

Study Designs and Outcomes Examined

Research into the management of primary apnoea has included a number of large, short-term Randomized Controlled Trials (RCTs), systematic Meta-analyses, and post-approval Post-authorization Safety Studies (PASS).

Study designs: Peyona was studied for short-term changes through double-blind RCTs, which involved comparisons against an inactive substance (placebo).
Outcomes monitored: The main measurements research examined included tracking the frequency and severity of apneic episodes. Specifically, researchers monitored outcomes such as the elimination of breathing pauses or tracking a predetermined reduction in the frequency of episodes (e.g., a ge50% reduction). They also tracked measures of treatment failure, such as when assisted ventilation became necessary.

Long-Term Research and Follow-up Studies

This research has explored long-term outcomes, rather than just the immediate breathing symptoms.

What Outcomes Were Tracked Over Time

Researchers monitored the health of these premature babies long after their initial treatment. Key measurements were evaluated in this context, including survival status without documentation of neurodevelopmental problems (such as those assessed at 18–21 months corrected age and up to 5 years). The research also examined the later incidence of Bronchopulmonary Dysplasia (BPD).

What Research is Still Needed and Unclear

It is important to understand that research is always ongoing, and certain aspects of Peyona's use remain uncertain or are still being actively studied.

Optimal Treatment Duration: The research currently provides limited insight into the ideal length of time a baby should receive this treatment. The total duration of the treatment course for the primary indication is not fully established across all clinical scenarios.
Dosage Studies: Research is ongoing to better understand the safety profile and patterns of effect associated with different or potentially higher dosage regimens.

Frequently Asked Questions (FAQ)

Common questions about Peyona (FAQ)

Q: What is Peyona used for?

According to official product information, Peyona is used to treat apnoea of prematurity, which involves premature babies stopping breathing for short periods. This treatment is generally reserved for situations where other supportive measures, like breathing support, have not been fully effective. It works by stimulating the baby's central nervous system, which is intended to support the regulation of breathing.

Q: How is Peyona given to the baby?

Peyona is administered to the baby by a healthcare professional directly into a vein (intravenous, or IV, administration). As this is a specialized treatment, it is always given in a hospital setting, typically by a neonatologist. The dosage is determined and calculated by the specialist based on the baby's body weight.

Q: How long does the treatment with Peyona usually last?

Regulatory documents state that treatment usually continues until the premature baby has been free of apnoea episodes for a period of 5 to 7 days. Alternatively, treatment may stop when the baby reaches 37 weeks post-menstrual age, whichever comes sooner. If the specialist determines there is no therapeutic benefit after 5–7 days of appropriate dosing, the treatment may be discontinued.

Q: What are the most common side effects of Peyona?

Official product information indicates that the most common side effects seen with Peyona are considered very common. These include transient tachycardia (a temporary fast heartbeat) and hyperglycaemia (high blood sugar levels). Hyperglycaemia may be associated with increased glucose intolerance.

Q: Can Peyona cause problems with the baby’s heart?

Studies and official information indicate that Peyona can cause a temporary fast heart rate, called transient tachycardia, which is listed as a very common side effect. Due to this potential effect, heart function is monitored by healthcare professionals during the treatment period.

Q: Why is it important to monitor the baby's glucose (sugar) levels during treatment?

According to regulatory sources, it is important to monitor the baby's blood glucose levels because Peyona can commonly cause hyperglycaemia (high blood sugar). This effect is a very common side effect and requires careful monitoring by the healthcare team.

Q: Can Peyona be mixed with other IV fluids or medicines?

Regulatory documents state that Peyona is compatible with the standard infusion fluids typically used in a neonatal intensive care setting. However, to prevent potential incompatibilities or dosing errors, the official documentation advises against mixing Peyona with any other medicine in the same syringe or infusion bag.

How should Peyona be stored and disposed of?

Peyona (caffeine citrate) solution for infusion and oral solution does not require special storage conditions prior to opening the ampoule. It should be kept out of the sight and reach of children. Do not use this medicine after the expiry date printed on the label.

Storage Condition	Detail
Unopened Ampoules	Does not require any special storage conditions.
After Opening	The solution must be used immediately.
Disposal	Any unused portion of the medicinal product left in the ampoule must be discarded. Disposal should be handled in accordance with local requirements for pharmaceutical waste by a healthcare professional, nurse, or pharmacist.